Indefinite Delivery Contract SPE2DX22D0129

The provided information describes a single-award Indefinite Delivery Contract (IDC) designated as SPE2DX, awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,999,999,999.00 ceiling value contract, which runs through December 31, 2031, enables the prime contractor to supply a comprehensive range of pharmaceutical products, medical supplies, and healthcare commodities to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government agencies. The contract covers a diverse array of pharmaceutical and medical products across multiple therapeutic domains, such as diabetes treatments, neurological medications, pain management pharmaceuticals, hormone treatments, antibiotics, and specialized medical supplies. The IDC is non-set-aside, allowing open competition, and facilitates the fulfillment of varied federal medical supply requirements through multiple delivery orders, positioning Amerisourcebergen Drug Corp as a critical vendor in supporting federal medical procurement needs.

The IDC originated from a Special Notice published by the DLA Medical Directorate in June 2020, seeking industry feedback on a draft Statement of Work for the upcoming National Prime Vendor Generation IV contract solicitation. The National Prime Vendor contract is intended to support the Defense Health Agency's TRICARE Pharmacy Program by providing replenishment of pharmaceutical and related products to multiple TRICARE pharmacy ordering facilities, as well as readiness support and backup to the CONUS Pharmaceutical Prime Vendor contracts.